Radalbuvir
Radalbuvir
Radalbuvir (pronounced: rah-dahl-buh-veer) is an experimental antiviral drug developed for the treatment of Hepatitis C. It is a nucleotide analogue that inhibits the RNA polymerase enzyme, which is essential for the replication of the Hepatitis C virus.
Etymology
The name "Radalbuvir" is a portmanteau of the words "RNA" and "antiviral", reflecting its mechanism of action against the Hepatitis C virus. The suffix "-buvir" is common in antiviral drugs, particularly those targeting Hepatitis C.
Mechanism of Action
Radalbuvir works by inhibiting the RNA polymerase enzyme, a key component in the replication process of the Hepatitis C virus. By blocking this enzyme, Radalbuvir prevents the virus from replicating and spreading within the host.
Related Terms
- Antiviral drug: A type of medication used to treat viral infections. Radalbuvir is an example of an antiviral drug.
- Hepatitis C: A viral infection that causes liver inflammation and damage. Radalbuvir is being developed to treat Hepatitis C.
- RNA polymerase: An enzyme that is crucial for the replication of the Hepatitis C virus. Radalbuvir inhibits this enzyme to prevent the virus from replicating.
- Nucleotide analogue: A type of antiviral drug that mimics the building blocks of the viral RNA. Radalbuvir is a nucleotide analogue.
External links
- Medical encyclopedia article on Radalbuvir
- Wikipedia's article - Radalbuvir
This WikiMD article is a stub. You can help make it a full article.
Languages: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
Urdu,
বাংলা,
తెలుగు,
தமிழ்,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
European
español,
Deutsch,
français,
русский,
português do Brasil,
Italian,
polski